Risk factors of early death in adult patients with secondary hemophagocytic lymphohistiocytosis: a single-institution study of 171 Chinese patients

被引:38
|
作者
Zhao, Yanchun [1 ]
Lu, Danlei [1 ]
Ma, Shanshan [1 ]
Li, Li [1 ]
Zhu, Jingjing [1 ]
Zhou, De [1 ]
Zheng, Yanlong [1 ]
Yang, Xiudi [1 ]
Zhu, Lixia [1 ]
Zhu, Mingyu [1 ]
Xie, Mixue [1 ]
Sun, Jianai [1 ]
Ye, Xiujin [1 ]
Xie, Wanzhuo [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Hematol, Hangzhou, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
Hemophagocytic lymphohistiocytosis; adult; early death; risk factors; malignancy; platelet; prognosis; risk stratification; PROGNOSTIC-FACTORS; CLINICAL CHARACTERISTICS; CASE-SERIES; OUTCOMES; CHILDREN; MULTICENTER; ACTIVATION; MUTATIONS; PLATELETS; FEATURES;
D O I
10.1080/16078454.2019.1660458
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Adult secondary hemophagocytic lymphohistiocytosis (HLH) is a potentially life-threatening syndrome characterized by excessive activation of mononuclear-phagocytic system resulting in hyperinflammatory response. To date, the factors influencing early death of HLH are still not fully elucidated. Patients and Methods: We did a retrospective study of 171 adult patients with newly diagnosed HLH at our institution from January 2012 to April 2018. All patients' clinical features, laboratory findings, treatments and prognosis were reviewed. Results: The median age was 49 years (range, 18-88 years), and 110 (64.3%) were male. The major underlying trigger of HLH was malignancy (88/171, 51.5%), especially non-Hodgkin lymphoma. In a multivariate analysis, age >= 54 years (P = 0.002), platelet <= 39.5 x 10(9)/L (P = 0.028), activated partial thromboplastin time (APTT) >= 54 sec (P = 0.048), triglyceride >= 3.23 mmol/L (P < 0.001), lactate dehydrogenase (LDH) >= 1300 U/L (P = 0.012) and malignancy (P = 0.001) were significantly associated with early death in HLH. Then, patients were classified into four groups according to the number of risk factors at the time of diagnosis: low risk (zero, one or two risk factors), low intermediate risk (three risk factors), high intermediate risk (four risk factors) and high risk (at least five risk factors), with the 30-day overall survival (OS) of 92.4%, 58.8%, 30.0% and 4.8%, respectively (P < 0.001). Conclusions: Patients with old age, thrombocytopenia, prolonged APTT, hypertriglyceridemia, elevated LDH and malignancy had inferior survival. It is important to identify those patients at risk of early death, which may guide treatment and reduce mortality.
引用
收藏
页码:606 / 612
页数:7
相关论文
共 50 条
  • [11] A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study
    Sang Eun Yoon
    Yeonghee Eun
    Kyungmin Huh
    Chi Ryang Chung
    In Young Yoo
    Junhun Cho
    Duck Cho
    Young Hyeh Ko
    Silvia Park
    Won Seog Kim
    Seok Jin Kim
    Annals of Hematology, 2020, 99 : 2095 - 2104
  • [12] Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis
    Otrock, Zaher K.
    Eby, Charles S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (03) : 220 - 224
  • [13] Clinical analysis and a novel risk predictive nomogram for 155 adult patients with hemophagocytic lymphohistiocytosis
    Lu, Mengxin
    Xie, Yanghao
    Guan, Xiaoxu
    Wang, Ming
    Zhu, Lin
    Zhang, Shen
    Ning, Qin
    Han, Meifang
    ANNALS OF HEMATOLOGY, 2021, 100 (09) : 2181 - 2193
  • [14] Elevated serum myoglobin levels at hospital admission and the risk of early death among patients with hemophagocytic lymphohistiocytosis: evidence from 155 pediatric patients
    Li, Xun
    Yan, Haipeng
    Zhang, Xinping
    Huang, Jiaotian
    Xiang, Shi-Ting
    Yao, Zhenya
    Zang, Ping
    Zhu, Desheng
    Xiao, Zhenghui
    Lu, Xiulan
    ANNALS OF HEMATOLOGY, 2020, 99 (05) : 963 - 971
  • [15] Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study
    Kim, Ju Yeon
    Kim, Miso
    Park, Jin Kyun
    Lee, Eun Bong
    Park, Jun Won
    Hong, Junshik
    ORPHANET JOURNAL OF RARE DISEASES, 2022, 17 (01)
  • [16] Hyperferritinemia in Hemophagocytic Lymphohistiocytosis: A Single Institution Experience in Pediatric Patients
    Basu S.
    Maji B.
    Barman S.
    Ghosh A.
    Indian Journal of Clinical Biochemistry, 2018, 33 (1) : 108 - 112
  • [17] Clinical characteristics and risk factors for 90-day overall survival among 204 adult patients with secondary hemophagocytic lymphohistiocytosis: Experience from a single-center retrospective study
    Wang, Dongguang
    Tong, Xiang
    Liu, Sitong
    Zhang, Wentao
    Wang, Lian
    Zhang, Shijie
    Zhang, Tianli
    Wang, Qian
    Fan, Hong
    FRONTIERS IN MEDICINE, 2022, 9
  • [18] Clinical Features of Hepatic Manifestations among Adult Patients with Hemophagocytic Lymphohistiocytosis: A Retrospective Study
    Bao, Qiongling
    Xu, Zhengqing
    Yang, Fengling
    Lu, Juan
    ACTA HAEMATOLOGICA, 2024, 147 (05) : 525 - 533
  • [19] Hemophagocytic lymphohistiocytosis: A series of five clinical cases in adult patients at a single institution with a review of the literature
    Thomas, David
    Shah, Nihar
    Patel, Hiren
    Pandya, Tapan
    Gauchan, Dron
    Maroules, Michael
    NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES, 2015, 7 (09) : 415 - 420
  • [20] Risk factors of early death in pediatric hemophagocytic lymphohistocytosis: Retrospective cohort study
    Zhang, Lijun
    Dai, Lei
    Li, Deyuan
    FRONTIERS IN PEDIATRICS, 2022, 10